Guido Oelkers har utsetts till ny vd för läkemedelsbolaget Sobi, med och har tidigare varit vd för det svenska medicinteknikbolaget Gambro.

Guido Oelkers joins Sobi from his previous role as CEO at BSN from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro,

Guido Oelkers was born in 1965 and holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London. He complemented his postgraduate studies in Economics at London School of Economics and Political Science. “We are delighted to announce Guido’s appointment. Guido Oelkers is affiliated with Swedish Orphan Biovitrum AB, Sartorius AG, BSN Medical GmbH, Gambro AB, Takeda Pharmaceuticals International GmbH, Invida Group Pte Ltd., BSN medical International Holding GmbH & Co. KG, Gambro Lundia AB, BSN Medical BV, Takeda A/S, Meda AB, Aventis Pharma Deutschland GmbH Guido Oelkers, VD och koncernchef Gambro +46 46 16 97 07 Om EQT EQT är det ledande riskkapitalbolaget i norra Europa med mer än EUR 19 miljarder i förvaltat kapital och flera investeringsstrategier. Guido Oelkers, President and CEO Gambro +46 46 16 97 07 About EQT EQT is the leading private equity group in Northern Europe with over EUR 19 billion in raised capital and multiple investment strategies.

15. Mai 2017 München 15.05.17. Swedish Orphan Biovitrum AB (SobiTM) ernennt Guido Oelkers zum Präsident und Chief Executive Officer. Am 22. 30 Oct 2013 See what employees say it's like to work at Gambro Renal Products. Salaries, reviews, and more - all Guido Oelkers. 3 Ratings.

16 maj 2017 Geoffrey McDonough lämnar, och Guido Oelkers tar över som och hälsovårdsföretag, bland annat från tiden som vd för Gambro och Invida. 15.

gaembrel gambrill gaembril gambro gaembrou gamco gaemkou game geym guiding gayding guido gwiydou guidone giydouniy guidotti giydoutiy guidroz oulk oelkers oulkoerz oelman oulmen oelrich oulrik oelschlager oulshleygoer

Guido Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH. Guido Oelkers. Chief Executive Officer Pharmaceutical Sobi Sweden. Biography.

Investor and EQT to sell Gambro to Baxter. Investor (49%) and EQT IV (51%) have signed an agreement to divest Gambro to the medical technology company Baxter International Inc (“Baxter”) for a total enterprise value of SEK 26.5 bn. The value of Gambro’s equity is SEK 18.3 bn. after deducting net debt of SEK 8.2 bn. (net debt as of signing).

Guido Oelkers ist eine Unternehmerpersönlichkeit, die an der Spitze von 8 verschiedenen Unternehmen gestanden hat. Dr. Oelkers ist President & Chief Executive Officer für Swedish Orphan Biovitrum AB, Chief Executive Officer von BSN medical BV und Chief Executive Officer & Director bei BSN medical International Holding GmbH & Co. KG. Er ist auch im Vorstand von Dova Pharmaceuticals, Inc. und Nätverkskopplingar. 22 direkta kopplingar, 5 män, 7 kvinnor, 11 bosatt utomlands.. Guido Oelkers. 55 år Mr Oelkers will succeed the outgoing CEO, Geoffrey McDonough. He will relocate to Sweden, where the drugmaker is based. Mr Oelkers has held the top role at several healthcare companies, including BSN Medical GmbH and Gambro.

15. Mai 2017 München 15.05.17. Swedish Orphan Biovitrum AB (SobiTM) ernennt Guido Oelkers zum Präsident und Chief Executive Officer. Am 22.
Inköpspris translate engelska

Jag är mycket glad över denna transaktion då Gambro tillsammans med Baxter nu kommer att ha resurser, teknologi och innovationskapacitet för att forma vår industri för framtiden, säger Guido Oelkers, vd och koncernchef för Gambro, i ett pressmeddelande. Guido Oelkers joins Sobi from his previous role as CEO at BSN from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro, In the past Guido Oelkers occupied the position of Group Chief Executive Officer of BSN medical GmbH, Chief Executive Officer at BSN Medical Holding, President & Chief Executive Officer at Gambro AB, President & Chief Executive Officer for Gambro Lundia AB, Chief Executive Officer of Invida Group Pte Ltd., Executive Vice President-Commercial Operations at Takeda A, Principal at Aventis Pharma Kontakt: Harry Klagsbrun, Partner på EQT Partners i Sverige, +46 8 506 55 323 Johan Hähnel, Talesperson för EQT IV, +46 8 506 55 334 Guido Oelkers, VD och koncernchef Gambro +46 46 16 97 07 Om EQT EQT är det ledande riskkapitalbolaget i norra Europa med mer än EUR 19 miljarder i förvaltat kapital och flera investeringsstrategier. 2017-05-04 · Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Jag är mycket glad över denna transaktion då Gambro tillsammans med Baxter nu kommer att ha resurser, teknologi och innovationskapacitet för att forma vår industri för framtiden, säger Guido Oelkers, vd och koncernchef för Gambro. STOCKHOLM (Direkt) Guido Oelkers har utsetts till ny vd för läkemedelsbolaget Sobi, med tillträde den 22 maj.

Global Dr. Guido Oelkers joined as President and CEO of Gambro in 2011. A capital injection was provided in June 2012 to support the first phase of the new Full Potential … Guido Oelkers appointed President and CEO at Sobi Thu, May 04, 2017 08:00 CET. Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Guido Oelkers has been appointed President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough. Guido Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH.
Vi föräldrar gravid

5 Dec 2012 Based in Lund in southern Sweden, Gambro, a provider of dialysis and therapies,” Gambro CEO Guido Oelkers said in the statement.

2017-05-04 · Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Jag är mycket glad över denna transaktion då Gambro tillsammans med Baxter nu kommer att ha resurser, teknologi och innovationskapacitet för att forma vår industri för framtiden, säger Guido Oelkers, vd och koncernchef för Gambro. STOCKHOLM (Direkt) Guido Oelkers har utsetts till ny vd för läkemedelsbolaget Sobi, med tillträde den 22 maj. Det framgår av ett pressmeddelande. Han kommer från en tidigare roll som vd för BSN Medical, det medicinteknikbolag som EQT sålde till SCA i december, och har tidigare varit vd för det svenska medicinteknikbolaget Gambro. Swedish Orphan Biovitrum announces that Guido Oelkers has been appointed President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough.